logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10188642 B1

PDFFull Text
Date of Patent:
Jan. 29, 2019

Filed:

Dec. 22, 2017

Pharmacologically active compounds

Applicant:

Cancer Research Technology Limited, London, GB;

Inventors:

Swen Hoelder, London, GB;

Julian Blagg, London, GB;

Kwai-Ming Jack Cheung, London, GB;

Butrus Atrash, London, GB;

Peter Sheldrake, London, GB;

Assignee:

Cancer Research Technology Limited, London, GB;

Attorneys:

Foley Hoag LLP

David P. Halstead

Primary Examiner:

Zinna Northington Davis

Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/541 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); A61K 31/4375 (2006.01); A61K 31/4725 (2006.01); A61K 31/4747 (2006.01); A61K 31/4985 (2006.01); A61K 31/5355 (2006.01); C07D 491/107 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4725 (2013.01); A61K 31/4375 (2013.01); A61K 31/4747 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5355 (2013.01); A61K 31/541 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/107 (2013.01);
Abstract

The present invention relates to compounds of formula II wherein X, Y, R, R, Rand Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

Find Patent Forward Citations

Loading…